Anti-diabetic effect of blockade of the renin-angiotensin system

Authors

  • Katsuyuki Ando,

    1. Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    Search for more papers by this author
  • Toshiro Fujita

    Corresponding author
    1. Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
      Toshiro Fujita, MD, Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Hongo 7-2-1, Bunkyo-ku, Tokyo 113-8655, Japan.
      E-mail:
      fujita-dis@h.u-tokyo.ac.jp
    Search for more papers by this author

Toshiro Fujita, MD, Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Hongo 7-2-1, Bunkyo-ku, Tokyo 113-8655, Japan.
E-mail:
fujita-dis@h.u-tokyo.ac.jp

Abstract

Diabetes, which is frequently associated with hypertension, accelerates the development of hypertension-induced cardiovascular disease. Thus, the prevention of diabetes is important in the management of hypertension. Recent clinical megastudies have suggested that the blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibits new onset of diabetes. Thus, the agents to inhibit the RAS should be beneficial for glucose metabolism. However, the cardiovascular protective effects of ACE inhibitors and ARBs are not always superior to other classes of drugs. Further long-term clinical trials are necessary to clarify the anti-diabetic effect of the RAS-inhibiting agents.

Ancillary